Ph3 Study of RMC-6236 in previously treated patients with RAS-Mutant NSCLC

Phase III Clinical Trial

RASolve 301: Phase 3 Multicenter Open Label Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT]NSCLC (RMC-6236-301)

Indication: Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer
Trial Number: 06881784
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations